# Iovance Biotherapeutics, Inc. Common Stock (IOVA)

> Iovance Biotherapeutics, Inc. Common Stock (IOVA) trades at $7.76 (+1.70%) as of 7:58:27 PM EST on Nov 13, 2026, -47.28% over the past month. Market cap is $3.53B, with 4.2 days to cover in short interest.

Canonical: https://massive.com/quote/iova
Data as of: 2026-11-14T00:58:27.005Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$7.76** +0.13 (+1.70%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$7.74** -0.02 (-0.26%)
As of 7:58:27 PM EST on Nov 13, 2026 · After hours

## Stock performance

How Iovance Biotherapeutics, Inc. Common Stock (IOVA) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.70% |
| 1W | -3.48% |
| 1M | -47.28% |
| YTD | +184.25% |
| 1Y | +220.66% |
| 52-wk range | $2.08 – $15.37 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for IOVA: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $7.46 – $7.83 |
| Open | $7.80 |
| Prev close | $7.63 |
| Volume | 11.68M |
| Market cap | $3.53B |
| Shares out | 452.97M |

## Valuation and profitability ratios

Valuation and profitability ratios for Iovance Biotherapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 9.31 |
| P/B | 4.34 |
| P/FCF | — |
| ROE | -27.1% |
| ROA | -22.3% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 12, 2026

## Insider trading

[Iovance Biotherapeutics, Inc. Common Stock (IOVA) insider trading](https://massive.com/quote/iova/insider-trading.md): open-market Form 4 buys and sells by Iovance Biotherapeutics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Iovance Biotherapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Iovance Biotherapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026, and an update on recent developments.”
- Nov 5, 2026 · Investor presentation
  “On November 5, 2026, Iovance Biotherapeutics, Inc. (the "Company") updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.”
- Oct 29, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On October 29, 2026, Iovance Biotherapeutics, Inc. (the "Company") issued a press release announcing updated results from Cohorts 1 and 2 of the Company's Phase 2 IOV-LUN-202 trial and a biomarker-enriched precision tumor infiltrating lymphocyte strategy for lifileucel in previously treated non-squamous metastatic non-small-cell lung cancer.”
- Oct 5, 2026 · Investor presentation
  “On October 5, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.1.”
- Sep 29, 2026 · [Guidance issuance or update](https://massive.com/quote/sec-filings/8-k/guidance-updates.md)
  “On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press release updating its full year 2026 revenue guidance.”

## IOVA short interest

How heavily IOVA is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.2 |
| Short interest | 65.19M |
| Avg volume | 15.64M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## IOVA news

The latest news and headlines about Iovance Biotherapeutics, Inc. Common Stock (IOVA).

- [IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress](https://www.zacks.com/stock/news/3025201/iova-q3-earnings-call-highlights-amtagvi-growth-and-pipeline-progress?cid=CS-ZC-FT-analyst_blog_plus|earnings_call_takeaways-3025201) · Zacks Investment Research · Nov 6, 2026 · positive sentiment
- [AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised](https://www.zacks.com/stock/news/3023086/amrx-q3-earnings-sales-beat-estimates-fy-26-guidance-raised?cid=CS-ZC-FT-analyst_blog|earnings_article-3023086) · Zacks Investment Research · Nov 4, 2026 · positive sentiment
- [Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?](https://www.zacks.com/stock/news/3021800/viatris-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-3021800) · Zacks Investment Research · Nov 3, 2026 · positive sentiment
- [Iovance Gears Up to Report Q3 Earnings: Here's What to Expect](https://www.zacks.com/stock/news/3020914/iovance-gears-up-to-report-q3-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-3020914) · Zacks Investment Research · Nov 2, 2026 · positive sentiment
- [GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth](https://www.zacks.com/stock/news/3019881/gild-beats-q3-earnings-on-hiv-strength-trodelvy-sales-growth?cid=CS-ZC-FT-analyst_blog|earnings_article-3019881) · Zacks Investment Research · Oct 30, 2026 · positive sentiment

## About Iovance Biotherapeutics, Inc. Common Stock

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 975 |
| Listed | May 26, 2010 |

[Company website](https://www.iovance.com)

## FAQ

### What is the Iovance Biotherapeutics, Inc. Common Stock (IOVA) stock price today?

Iovance Biotherapeutics, Inc. Common Stock (IOVA) is trading at $7.76 (+1.70% on the day) as of 7:58:27 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Iovance Biotherapeutics, Inc. Common Stock?

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient.

### What is the short interest in IOVA?

As of Oct 30, 2026, IOVA has 65.19M shares short and 4.2 days to cover.

### What exchange is IOVA listed on?

Iovance Biotherapeutics, Inc. Common Stock (IOVA) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time IOVA quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=IOVA`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Iovance Biotherapeutics, Inc. Common Stock (IOVA) insider trading](https://massive.com/quote/iova/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms